文献速递其他结缔组织病自身炎症与 IgG4 相关病

免疫检查点抑制剂相关肌炎的治疗策略与再挑战安全性:全国多中心研究

Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该全国多中心回顾性研究纳入20例无心肌受累的免疫检查点抑制剂相关肌炎(irM)患者,其中16例为典型irM、4例为非典型irM。典型irM以类固醇单药治疗为主,多数完全缓解;非典型irM需更强免疫抑制且预后较差。9例中重度irM患者在症状缓解和CK正常化后重新使用ICI,结果支持再挑战的安全性。

要点

  • 典型irM以类固醇单药治疗有效,非重症低剂量与高剂量口服泼尼松疗效相同。
  • 非典型irM需更强免疫抑制,预后较差,可出现irM相关死亡。
  • 中重度irM在症状缓解和CK正常化后重新使用ICI,结果支持安全性。

核心结论

  • 类固醇单药是典型irM的有效治疗,可根据严重程度选择口服泼尼松或静脉甲泼尼龙冲击。
  • 识别非典型特征对确定初始治疗策略很重要。
  • 中重度irM在症状缓解和CK正常化后重新使用ICI,结果支持安全再挑战。

研究设计与样本

  • 2018年4月至2020年3月开展的全国多中心回顾性研究,纳入20例无心肌受累的irM患者。
  • 根据有无皮肤体征或异常组织病理学特征,将患者分为典型irM(16例)和非典型irM(4例)。
  • 分析两组的治疗策略,并回顾ICI再挑战的方式和结局。

主要发现

  • 16例典型irM中,14例接受类固醇单药治疗,均在≤3周内完全缓解。
  • 非重症典型irM(10例)口服类固醇,低剂量(≤0.5 mg/kg/day)与高剂量(1 mg/kg/day)疗效相同。
  • 重症典型irM经静脉甲泼尼龙治疗成功。
  • 非典型irM(4例)演化较差,包括1例irM相关死亡,需要强免疫抑制。
  • 9例中重度irM患者(中度6例、重度3例)安全重新使用ICI。

关键数值与推荐

  • 非重症典型irM口服类固醇低剂量为≤0.5 mg/kg/day,高剂量为1 mg/kg/day,两者疗效相同。
  • 典型irM类固醇单药治疗后完全缓解时间≤3周。
  • ICI再挑战在症状缓解和肌酸激酶(CK)正常化后进行。

临床怎么用

  • 典型irM可根据严重程度采用口服泼尼松或静脉甲泼尼龙冲击作为初始治疗。
  • 需识别非典型irM特征,此类患者可能需要更强免疫抑制治疗。
  • 中重度irM患者在症状缓解和CK正常化后可考虑安全重新使用ICI。

局限性

  • 样本量较小(共20例),非典型irM仅4例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The occurrence of immune-related myositis (irM) is increasing, yet there are no therapeutic guidelines. We sought to analyse the current therapeutic strategies of irM and evaluate the outcomes of immune checkpoint inhibitors (ICIs) rechallenge. METHODS: We conducted a nationwide retrospective study between April 2018 and March 2020 including irM without myocardial involvement. Depending on the presence of cutaneous signs or unusual histopathological features, patients were classified into two groups: typical or atypical irM. Therapeutic strategies were analysed in both groups. The modalities and outcomes of ICI rechallenge were reviewed. RESULTS: Among the 20 patients, 16 presented typical irM. Regardless of severity, most typical irM were treated with steroid monotherapy (n = 14/16) and all had a complete response within ≤3 weeks. The efficacy of oral steroids for non-severe typical irM (n = 10) was the same with low-dose (≤0.5 mg/kg/day) or high-dose (1 mg/kg/day). Severe typical irM were successfully treated with intravenous methylprednisolone. Atypical irM (n = 4) had a less favourable evolution, including one irM-related death, and required heavy immunosuppression. ICIs were safely reintroduced in nine patients presenting a moderate (n = 6) or a severe (n = 3) irM. CONCLUSION: Our data highlight that steroid monotherapy is an effective treatment for typical irM, either with prednisone or with intravenous methylprednisone pulses depending on the severity. The identification of unusual features is important in determining the initial therapeutic strategy. The outcomes of rechallenged patients are in favour of a safe reintroduction of ICI following symptom resolution and creatin kinase (CK) normalization in moderate and severe forms of irM.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Weill A, Delyon J, Descamps V, et al. Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology (Oxford). 2021. PMID: 33725115. doi:10.1093/rheumatology/keab249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。